Iron therapies, erythropoiesis stimulating agents (ESAs), and hypoxia inducible factor inhibitors (HIF-PHI) are used to treat anemia of chronic kidney disease (CKD).
Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease. Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...
Clinicians and their patients with chronic kidney disease (CKD) need to be aware of zinc intake and anemia status.
The confluence of CKD, renal anemia, and atrial fibrillation is common and has implications for anticoagulation. Renal anemia affects every 3 out of 5 patients with atrial fibrillation and advancing ...
TSUKUBA, JAPAN — Anemia and chronic kidney disease (CKD) are independently associated with an increased risk of new-onset atrial fibrillation (AF), and the combination of the two risk factors is ...
In this study, both anemia and chronic kidney disease were highly prevalent among HF patients discharged from two university hospitals and independently associated with an increased risk of dying in ...
Please provide your email address to receive an email when new articles are posted on . Overall, 27.2% of patients had serum ferritin at or below 100 ng/mL. The study also found that 13.1% of patients ...
SGLT2 inhibitors may be a useful adjunct therapy to reduce anemia risk in patients with type 2 diabetes and early CKD. Anemia risk is lower among patients receiving SGLT2 inhibitors (SGLT2i) compared ...
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...
Anemia and other contributing factors are common causes of fatigue in chronic kidney disease (CKD). Healthy lifestyle habits and taking steps to meet your nutritional needs can help. If you have ...